# US 2025/0082867 A1 · Interventional catheter, interventional device, nebulized medication delivery system, control method, nebulization method, spray system and method of treating medium

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082867 A1
- Document ID: US20250082867A1
- Status: Published application
- Kind: A1
- Application number: 18/959,748
- Filed: 2024-11-26
- Published: 2025-03-13
- Earliest claimed: 2022-05-26
- Assignees: Hangzhou Broncus Medical Co., Ltd.
- Applicants: Hangzhou Broncus Medical Co., Ltd.
- Inventors: Hong Xu; Maoqiang Wang; Pengwei Xu
- Web page: https://patentgrep.com/patent/US20250082867A1

## CPC

- A61M 11/001: {Particle size control}
- A61M 11/06: of the injector type
- A61M 11/02: operated by air {or other gas} pressure applied to the liquid {or other product} to be sprayed or atomised {(sprayers for horticulture A01G, A01H; killing insects A01M; air humidifying by nozzles F24F6/14, F24F6/18; cooling by spraying F28B, F28C)}
- A61M 25/00: Catheters; Hollow probes (dilators A61M29/00; {peritoneal catheters A61M1/285; tracheal tubes A61M16/04; for drainage A61M27/00; for uterus, vagina or rectum A61M31/00} ; for measuring or testing A61B; {materials for catheters A61L29/00})
- A61M 25/0021: {characterised by the form of the tubing (A61M25/0054 takes precedence)}
- A61M 25/10: Balloon catheters ({A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02;} inflatable balloons for placing stents or stent-grafts A61F2/958 {; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00})
- A61M 31/00: Devices for introducing or retaining media, e.g. remedies, in cavities of the body (A61M25/00 takes precedence {; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008})
- G01D 21/02: Measuring two or more variables by means not covered by a single other subclass
- H03K 17/60: the devices being bipolar transistors (bipolar transistors having four or more electrodes H03K17/72)
- H03K 17/687: the devices being field-effect transistors
- A61M 11/041: {using heaters}
- A61M 16/208: {Non-controlled one-way valves, e.g. exhalation, check, pop-off non-rebreathing valves}
- A61M 16/209: {Relief valves}
- A61M 2202/0007: introduced into the body
- A61M 2202/02: Gases
- A61M 2202/04: Liquids
- A61M 2202/0468: non-physiological
- A61M 2202/206: Viruses
- A61M 2205/07: having air pumping means
- A61M 2205/18: with alarm
- A61M 2205/3306: Optical measuring means
- A61M 2205/3334: Measuring or controlling the flow rate
- A61M 2205/3355: Controlling downstream pump pressure
- A61M 2205/3368: Temperature
- A61M 2205/3606: cooled
- A61M 2205/366: by liquid heat exchangers
- A61M 2205/42: Reducing noise
- A61M 2205/50: with microprocessors or computers
- A61M 2205/505: Touch-screens; Virtual keyboard or keypads; Virtual buttons; Soft keys; Mouse touches
- A61M 2205/587: Lighting arrangements
- A61M 2205/6018: providing set-up signals for the apparatus configuration
- A61M 2205/6054: Magnetic identification systems
- A61M 2205/8206: battery-operated
- A61M 2205/8218: Gas operated
- A61M 2206/20: having means for promoting or enhancing the flow, actively or passively
- A61M 2210/1039: Lungs
- A61M 2230/04: Heartbeat characteristics, e.g. ECG, blood pressure modulation
- Y02P 90/02: Total factory control, e.g. smart factories, flexible manufacturing systems [FMS] or integrated manufacturing systems [IMS]
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- G01D: MEASURING NOT SPECIALLY ADAPTED FOR A SPECIFIC VARIABLE; ARRANGEMENTS FOR MEASURING TWO OR MORE VARIABLES NOT COVERED IN A SINGLE OTHER SUBCLASS; TARIFF METERING APPARATUS; MEASURING OR TESTING NOT OTHERWISE PROVIDED FOR
- H03K: PULSE TECHNIQUE (measuring pulse characteristics G01R; modulating sinusoidal oscillations with pulses H03C; transmission of digital information H04L; discriminator circuits detecting phase difference between two signals by counting or integrating cycles of oscillation H03D3/04; automatic control, starting, synchronisation or stabilisation of generators of electronic oscillations or pulses where the type of generator is irrelevant or unspecified H03L; coding, decoding or code conversion, in general H03M)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

A nebulized medication delivery method includes: providing an interventional catheter, nebulizing a fluid containing a therapeutic substance through the interventional catheter and delivering nebulized fluid to a lesion site; wherein the fluid includes a liquid-phase fluid and a gas-phase fluid, and at least one of the liquid-phase fluid and the gas-phase fluid carries the therapeutic substance.

## Claims

### Claim 1

A nebulized medication delivery method, comprising:
providing an interventional catheter; and
nebulizing a fluid containing a therapeutic substance through the interventional catheter and delivering nebulized fluid to a lesion site;
wherein the fluid comprises a liquid-phase fluid and a gas-phase fluid, and at least one of the liquid-phase fluid and the gas-phase fluid carries the therapeutic substance.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising:
providing a perfusion device for supplying the liquid-phase fluid and the gas phase-fluid;
connecting the interventional catheter to the perfusion device for receiving the gas-phase fluid and the liquid-phase fluid, respectively;
presetting working parameters of the gas-phase fluid and the liquid-phase fluid, and controlling the perfusion device accordingly.

### Claim 3 (depends on 1)

The method according to claim 1, further comprising:
pre-perfusing of the liquid-phase fluid and the gas-phase fluid into the interventional catheter, and determining whether the pre-perfusion is completed according to a duration of the pre-perfusion and/or a pressure change of the fluid,
wherein the gas-phase fluid is first supplied into the interventional catheter and then the liquid phase fluid is supplied into the interventional catheter during the pre-perfusion.

### Claim 4 (depends on 1)

The method according to claim 1, further comprising:
S1, presetting target pressures of the gas-phase fluid and at least two sets of PID parameters, and associating each target pressure with a corresponding set of PID parameters;
S2, proving the gas-phase fluid first to the interventional catheter and then the liquid-phase fluid to the interventional catheter, through a perfusion device;
S3, collecting a first real-time pressure of the gas-phase fluid through a sampling device, comparing the first real-time pressure with the target pressures and calling a corresponding set of PID parameters through a control device, and adjusting a pressure of the gas-phase fluid supplied by the perfusion device according to this corresponding set of PID parameters;
S4, collecting a second real-time pressure of the gas-phase fluid through the sampling device, comparing the second real-time pressure with the target pressures and calling a corresponding set of PID parameters through the control device, and adjusting the pressure of the gas-phase fluid supplied by the perfusion device according to this corresponding set of PID parameters;
S5, repeating step S4 at predetermined intervals.

### Claim 5 (depends on 4)

The method according to claim 4, further comprising step S6: setting a pressure threshold, collecting a real-time pressure of the gas-phase fluid and comparing the real-time pressure with the pressure threshold, wherein
when the real-time air pressure is greater than the pressure threshold, nebulization is stopped; and, when the real-time air pressure is not greater than the pressure threshold, the pressure of the gas-phase fluid is adjusted according to the corresponding set of PID parameters.

### Claim 6 (depends on 1)

The method according to claim 1, further comprising:
inserting an endoscope into a natural cavity of a human body, wherein the endoscope is configured with an endoscope channel, and the interventional catheter extends along the endoscope channel to a lesion site of the human body; and
retracting the endoscope with a distance of 1˜2 cm when a distal end of the endoscope reaches the lesion site, wherein the interventional catheter extends along the endoscope channel until a distal end thereof extends out of the endoscope channel.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the endoscope is configured for observing a nebulization effect during nebulization process, and at least one of the following operations is performed:
a) regulating a supply of the fluid;
b) pausing the nebulization process, adjusting the interventional catheter to change the lesion site corresponding to the interventional catheter, and then continuing the nebulization process for the changed lesion site;
c) adjusting the interventional catheter to change the lesion site corresponding to the interventional catheter directly, and then continuing the nebulization process for the changed lesion site.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the supply of the liquid-phase fluid is stopped in the nebulization process when an amount of the supplied liquid-phase fluid reaches a preset value; while the gas-phase fluid is supplied continuously to a pipeline for delivering the liquid-phase fluid into the interventional catheter and an inlet for the liquid-phase fluid, so as to blow away residual liquid-phase fluid; and the supply of the gas-phase fluid is stopped until the liquid-phase fluid is completely nebulized.

### Claim 9 (depends on 8)

The method according to claim 8, further comprising:
setting a preset delay duration and blowing away the residual liquid-phase fluid according to the preset delay duration, wherein the supply of the gas-phase fluid is stopped when the preset delay duration is reached.

### Claim 10

A method for treating a natural cavity of a human body, comprising:
putting a therapeutic substance to a fluid;
nebulizing the fluid with the therapeutic substance and delivering nebulized fluid to a lesion site;
wherein the fluid comprises a liquid-phase fluid and a gas-phase fluid, and at least one of the liquid-phase fluid and the gas-phase fluid carries the therapeutic substance.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the therapeutic substance is a highly viscous fluid loaded in the liquid-phase fluid; and wherein, during nebulization,
a droplet size is controlled to be not less than 20 microns, a pressure of the liquid-phase fluid is controlled to be 0.2-0.76 MPa, and a pressure of the gas-phase fluid is controlled to be 0.1-0.4 Mpa.

### Claim 12 (depends on 10)

The method according to claim 10, wherein the therapeutic substance is cells loaded in the liquid-phase fluid, and a particle size of the cell is not larger than 120 microns; and wherein, during nebulization,
a droplet size is controlled to be 20-100 microns, and a pressure of the liquid-phase fluid is controlled to be 0.2-0.76 MPa, and a pressure of the gas-phase fluid is controlled to be 0.1-0.4 MPa.

### Claim 13 (depends on 12)

The method according to claim 12, wherein a flow rate of the liquid-phase fluid with the cells is 1-2 ml/min, a pressure of the gas-phase fluid is 0.1-0.15 MPa, a particle size the cells is in range of 20-50 microns, and a droplet size of the liquid-phase fluid is in range of 30-70 microns.

### Claim 14 (depends on 10)

The method according to claim 10, wherein the therapeutic substance is inactivated virus loaded in the liquid-phase fluid, and a particle size of the inactivated virus is not larger than 21 microns; and wherein, during nebulization,
a droplet size is controlled to be not larger than 300 microns, a pressure of the liquid-phase fluid is controlled to be 0.2-0.76 MPa, and a pressure of the gas-phase fluid is controlled to be 0.2-0.6 MPa.

### Claim 15 (depends on 10)

The method according to claim 10, wherein the therapeutic substance is a medication loaded in the liquid-phase fluid, and a particle size of the medication is not larger than 69 microns; and wherein, during nebulization,
a droplet size is controlled to not larger than 300 microns, a pressure of the liquid-phase fluid is controlled to be 0.2-0.76 MPa, and a pressure of the gas-phase fluid is controlled to be 0.2-0.6 MPa.

### Claim 16 (depends on 10)

The method according to claim 10, wherein the lesion site is a lung.

### Claim 17 (depends on 16)

The method according to claim 16, wherein diseases of the lung comprise asthma, lung tumors, chronic obstructive bronchitis, chronic obstructive pulmonary disease, parenchymal and fibrotic diseases, interstitial lung diseases and inflammation, bronchiolitis obliterans, and related diseases caused by acute and chronic organ transplant rejection after lung transplantation.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the therapeutic substance is nebulized and then delivered to the lung through an inhalation method or an interventional catheter.

### Claim 19

A nebulized medication delivery method, comprising:
providing a gas-phase fluid and a liquid-phase fluid, wherein at least one of the gas-phase fluid and the liquid-phase fluid carries a therapeutic substance;
pre-dispersing one of the gas-phase fluid and the liquid-phase fluid;
nebulizing the liquid-phase fluid by means of mixing the gas-phase fluid and the liquid-phase fluid together;
delivering nebulized fluid to a lesion site.

### Claim 20 (depends on 19)

The method according to claim 19, wherein nebulization of the liquid-phase fluid is achieved by means of mixing the gas-phase fluid and liquid-phase fluid at least twice.
